Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus ESMOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus ESMOLOL HYDROCHLORIDE.
BETAPACE vs ESMOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min; titrate by 25-50 mcg/kg/min every 5-10 minutes up to 200 mcg/kg/min.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: approximately 9 minutes in adults (range 4–13 min); in patients with hepatic impairment: unchanged; in severe renal impairment: prolonged to 12–20 min due to metabolite accumulation. Clinically, rapid offset (within 20–30 min) allows for titration.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Rapid metabolism by red blood cell esterases to inactive acid metabolite (ASL-8123) and methanol; <2% excreted unchanged in urine; primarily renal elimination of metabolites.
Category C
Category A/B
Beta-Blocker
Beta-Blocker